Treatment Access Solution
A collaboration with Novartis
The Max Foundation’s long-standing shared-value partnership with Novartis was first established in 2002 through the Glivec®International Patient Assistance Program, commonly known by its acronym GIPAP. GIPAP is operating in specific low and middle income countries providing access to Glivec® (imatinib) for people properly diagnosed with chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and orphan indications for which Glivec has been approved. Eligible patients, must meet medical and socio-economic criteria.
Throughout 2017, The Max Foundation and Novartis will be transitioning their partnership around access to Glivec® (imatinib) treatment from the GIPAP model to a new collaboration known as CMLPath to Care™.
CMLPath to Care is a unique global initiative that connects people living with chronic myeloid leukemia (CML) and their carers with effective treatments, professional medical capabilities, trained physicians and hands-on support. The initiative is directed by The Max Foundation with support from Novartis Oncology through drug donations and funding. CMLPath to Care is an evolved compact reflecting a new healthcare environment and the founders’ one simple goal – to enable people living with CML to be well.